MET and neoplasm: Similarly, Met-1 subclones also exhibited variable tumor incidence with 4 of 5 subclones (MT-2, MT-4, MT-24, and MT-29) forming tumors with ~100% incidence, while one subclone (MT-3) had reduced incidence to 50–66%, depending on the numbers of cells injected (Fig 3B).